Stem cell signature in glioblastoma: Therapeutic development for a moving target

Journal of Neurosurgery

Volumn 122, Issue 2, 2015, Pages 324-330

  Nakano, Ichiro ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Brain tumor; Cancer stem cells; Clonal evolution; GBM; Mesenchymal; Oncology; Tumor heterogeneity

Indexed keywords

TUMOR MARKER;

CELL PLASTICITY; CLINICAL TRIAL (TOPIC); GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; BRAIN NEOPLASMS; CANCER STEM CELL; CLASSIFICATION; MESODERM; NERVE CELL; NERVE CELL PLASTICITY; PATHOLOGY; PHENOTYPE; SYSTEMS BIOLOGY; TRENDS;

BRAIN NEOPLASMS; CELLULAR REPROGRAMMING; GLIOBLASTOMA; HUMANS; MESODERM; NEOPLASTIC STEM CELLS; NEURONAL PLASTICITY; NEURONS; PHENOTYPE; SYSTEMS BIOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84926076998     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2014.9.JNS132253     Document Type: Review

References (39)

1. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, et al: Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277, 2002
2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006
3. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-4015, 2007
4. Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12:715-723, 2011
5. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al: Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24:331-346, 2013
6. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al: The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 25:2594-2609, 2011
7. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al: The somatic genomic landscape of glioblastoma. Cell 155:462-477, 2013
8. Capela A, Temple S: LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron 35:865-875, 2002
9. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al: The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-325, 2010
10. Cheng L, Wu Q, Huang Z, Guryanova OA, Huang Q, Shou W, et al: L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J 30:800-813, 2011
11. Colman H, Aldape K: Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 65:877-883, 2008
12. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567, 2007
13. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 140:883-899, 2010
14. Güngör C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, et al: Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res 71:5009-5019, 2011
15. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
16. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al: Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382-3389, 2009
17. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, et al: NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569-581, 2004
18. Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ: The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 14:150-158, 2012
19. Lagadec C, Vlashi E, Delia Donna L, Dekmezian C, Pajonk F: Radiation-induced reprogramming of breast cancer cells. Stem Cells 30:833-844, 2012
20. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, et al: Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6:421-432, 2010
21. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL: uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 178:425-436, 2007
22. Liu Y, Han SS, Wu Y, Tuohy TM, Xue H, Cai J, et al: CD44 expression identifies astrocyte-restricted precursor cells. Dev Biol 276:31-46, 2004
23. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, et al: Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70:2030-2040, 2010
24. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-478, 2012
25. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al: VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21-35, 2012
26. Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, et al: Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A 110:8644-8649, 2013
27. Naline E, Sanceaume M, Toty L, Bakdach H, Pays M, Advenier C: Penetration of minocycline into lung tissues. Br J Clin Pharmacol 32:402-404, 1991
28. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, et al: YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 11:3326-3334, 2005
29. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006
30. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al: Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603-1615, 2011
31. Sakuma K, Aoki M, Kannagi R: Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A 109:7776-7781, 2012
32. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004
33. Son MJ, Woolard K, Nam DH, Lee J, Fine HA: SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4:440-452, 2009
34. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437, 2012
35. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, et al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70:9937-9948, 2010
36. Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y: Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol 35:171-176, 2008
37. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
38. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al: Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69:2400-2407, 2009
39. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG: Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke 37:1087-1093, 2006